Thai Ministry of Public Health and WHO Host Meeting of Leading Researchers to Highlight Burden of Meningitis and Pneumonia

Bangkok--30 Mar--Total Quality PR

* Hib and Pneumococcal Disease Two Major Causes of Life-Threatening Meningitis and Pneumonia in South Asian Children * Every year the deadly diseases meningitis and pneumonia kill an estimated 2 million children globally under the age of 5 years. Of these deaths, many occur in Africa and Asia. Experts are meeting in Bangkok this week will focus on two major life-threatening causes of pneumonia and meningitis: the bacteria Haemophilus influenzae type B (or “Hib”) and streptococcus pneumonia. Both pneumonia and meningitis are vaccine-preventable. The urgent need for a sustained effort to accelerate the prevention of meningitis and pneumonia formed the core of discussions amongst leading researchers attending a Ministry of Public Health and WHO meeting today. With Hib and pneumococcal diseases estimated to be responsible for up to 1.4 million child deaths globally each year - local efforts to measure the scale of the problem in Asia are gaining momentum. “Effective surveillance of meningitis and pneumonia has helped us to better understand the magnitude of the problem and help evaluate the impact of available vaccines”, commented Dr. Jean-Marie Okwo-Bele, Director, Department of Immunization Vaccines and Biologicals, WHO. Sadly children with HIV/AIDS are up to 40 times more likely to get pneumococcal disease than children without HIV/AIDS, and in countries such as Thailand where rates of HIV/AIDS are high, Hib and pneumococcal diseases place an additional burden on national health systems. Dr. Supamit Chunsuttiwat from the Ministry of Public Health, Thailand, said “the Thai government is committed to improving child survival and combating meningitis and pneumonia. Vaccines are a simple and effective health intervention, and while Thailand has high vaccine coverage rates, there is still much work to be done to introduce other vital vaccines. By partnering with governments and civil societies we can work faster together to prevent unnecessary death and suffering”. Dr Rana Hajjeh, The Hib Initiative, Project Director said: “systematic surveillance is critical to making evidence-based decisions for the introduction of pneumococcal and Hib vaccines. We could save millions of children’s lives and make a significant move towards meeting a key UN Millennium Development Goal of reducing child mortality by two thirds by 2015”. Dr. Orin Levine, Executive Director, GAVI’s PneumoADIP commented that now is an incredibly exciting time for those working in pneumococcal disease prevention. Through sustained financing from GAVI and an Advanced Market Commitment (AMC) vaccines are going to be reaching the children who need them as early as 2008. The Pneumococcal and Hib Surveillance Network Investigators meeting was sponsored by the World Health Organisation, GAVI’s PneumoADIP and the Hib Initiative and brought together experts from a number of Asian countries including, amongst others, Bangladesh, India, Indonesia, Republic of Korea, Mongolia, Nepal, Sri Lanka, Thailand and Viet Nam. The importance placed on this meeting reflects the global community’s increasing focus on meningitis and pneumonia, and the urgent need for a global solution. Further information can also be found at: www.HibAction.org and www.PreventPneumo.org For more information please contact: Hans Kvist Director, Communications GAVI’s PneumoADIP Mobile in Bangkok: +1 410 736 8243 Email: [email protected] Selina Haylock Consultant Ruder Finn Communications Mobile in Bangkok: +44 (0)7768 823 989 Email: [email protected] Lois Privor-Dumm, MIBS Director, Communications Strategy, The Hib Initiative Mobile in Bangkok: +1 484 354 8054 Email: [email protected] Tom Van Blarcom Total Quality PR (Thailand) Co., Ltd Tel. 02 260 5820 Fax 02 260 5847 – 8 E-mail : [email protected]

ข่าวPneumococcal Disease+Meningitisวันนี้

สมาพันธ์องค์การโรคเยื่อหุ้มสมองอักเสบขานรับนโยบายใหม่ของรัฐบาลฮ่องกง

บรูซ แลงกูแลนท์ ประธานสมาพันธ์องค์การโรคเยื่อหุ้มสมองอักเสบ (Confederation of Meningitis Organisations: CoMO) แสดงความชื่นชมการตัดสินใจของรัฐบาลฮ่องกงที่ให้มีการเพิ่มวัคซีนชนิดใหม่เข้าไปในโครงการฉีดวัคซีนสำหรับเด็ก โดยตั้งแต่นี้เป็นต้นไปเด็กๆ ในฮ่องกงที่เกิดหลังวันที่ 1 กันยายน พ.ศ.2550 จะได้รับวัคซีนป้องกันโรคที่เกิดจากการติดเชื้อนิวโมคอคคัส 7 ชนิด ซึ่งจะช่วยป้องกันเด็กๆ จากโรคไอพีดี (Invasive Pneumococcal Disease: IPD) “การเพิ่มวัคซีนใหม่เข้าไปในโครงการฉีดวัคซีนสำหรับเด็กถือเป็น

The Confederation of Meningitis Organisations (CoMO) Applauds the Actions of the Government of Hong Kong!

Bruce Langoulant, President of the Confederation of Meningitis Organisations (CoMO), applauds the Government of Hong Kong on the inclusion of a new vaccine to the Childhood Immunisation Program ...

Meningitis Organisations Worldwide Call on Asia Pacific Governments to Protect Children from Deadly Pneumococcal Disease

Data presented this week at the 6th International Symposium for Pneumococci and Pneumococcal Diseases (ISPPD-6) confirms that a universal pneumococcal vaccination programme would...

Thai Ministry of Public Health and WHO Host Meeting of Leading Researchers to Highlight Burden of Meningitis and Pneumonia

* Hib and Pneumococcal Disease Two Major Causes of Life-Threatening Meningitis and Pneumonia in South Asian Children * Every year the deadly diseases meningitis and pneumonia...

โรคไอพีดี หรือ IPD (Invasive Pneumococcal... โรคปอดติดเชื้อ IPD ภัยร้ายใกล้ตัวลูกน้อย — โรคไอพีดี หรือ IPD (Invasive Pneumococcal Disease) คือโรคติดเชื้อแบคทีเรียนิวโมคอคคัสชนิดรุนแรง ได้แก่ การติด...

ไอพีดี! ไม่ได้คุกคามแค่เด็ก ผู้สูงอายุก็ตกอยู่ในกลุ่มเสี่ยงโรคติดเชื้อรุนแรงเช่นกัน

คนส่วนใหญ่เข้าใจว่า โรคไอพีดี (Invasive Pneumococcal Disease : IPD) เป็นโรคที่มีความเสี่ยงต่อเด็กเท่านั้น ในความเป็นจริงผู้สูงอายุก็อยู่ในกลุ่มเสี่ยงด้วยเช่นกัน ผู้สูงอายุเป็นผู้ที่มีสุขภาพเปราะบาง เสี่ยงต่อการ...

Wyeth's Prevenar 13* Receives First Approval

-Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal...